ABSTRACT AKR/J mice, 80-90% of which ordinarily die of spontaneous lymphocytic leukemias by 12 months of age, were significantly protected from developing leukemia in the initial experiment by a single course of treatment with AKR serotype-specific antibodies made in goats and processed as immune gamma globulin (IgG). In experiment 1, IgG was given on the day of birth and on four additional days, and finished on day 14. This schedule resulted in suppression of over 4 logarithms of normal virogene expressions up to 25 days of age and led to partial viral suppression for over 200 days of age. At 365 days of age, 20 of 24 (83.3%) control animals were dead of leukemia whereas six of 30 (20%) treated animals had died of leukemia. In a second experiment, only four inoculations of IgG were given from birth to 20 days, after which they were given three inoculations of radiation-killed vaccine specific for AKR-Gross leukemia virus and one injection of murine sarcoma virus-Gross leukemia virus 10 days later. This combined immunization procedure provided significant virus suppression up to 288 days of age. At 300 days of age, 30 of the 50 (60%) controls had died of leukemia while only 1 of 24 (4.2%) of the immunized mice developed fatal leukemia; the significance of protection for each of the experiments was P << 0.001. We conclude that these data establish in classical fashion with type-specific immunosuppression the determining role of type-C endogenous virogenes in leukemogenesis and, at the same time, also establish the feasibility of nearly total prevention of leukemia in AKR mice.
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In this communication we report two experiments, both resulting in highly significant prevention of spontaneous leukemia in AKR/J mice. In the first experiment, several injections of virus-specific antisera prepared as immune gamma globulin (IgG) were given shortly after birth and continued to the 14th and 20th days of age, after which the control and immunized mice (starting at 170 days of age) were observed twice daily for development of the leukemia and/or thymic lymphomas which normally account for nearly all deaths in AKR mice by 12 months of age.
PROCEDURES
Preparation of IgG Antisera. The anti-AKR-specific antiviral IgG was prepared by injecting castrated male goats with 1000 times concentrated preparation of banded radiation leuikemia virus § of Lieberman and Kaplan (1) which had been grown in SC-I cells (2) . The goats, 12-18 months of age, were immunized intramuscularly at 1 to 2 week intervals with Abbreviations: GLV, Gross leukemia virus; MSV, murine sarcoma virus.
Radiation leukemia virus was selected as the desirable virogene prototype because in addition to having the same serotype specificity as does AKR virus, it replicated to higher titer in vitro and, when banded, the virion retained the integrity of its envelope to a much higher degree than did AKR or Gross leukemia virus preparations (3, 4 The anti-AKR neutralizing titers of the IgG pools were determined in the XC test using the SC-I cell as the susceptible cell system (2, 5) . IgG containing 1:800-1:1600 anti-AKR virus neutralizing titers were given subcutaneously in two experiments according to schedules shown in Table 1 . RESULTS XC tests on 2% extracts of tail segments of the immunized mice in both experiments as shown in Table 2 revealed almost complete suppression of infectious virus at 25 days of age. The suppression at 34 days of age was also impressive and persisted well beyond 200 days; it was still quite significant at 288 days of age in experiment 2. The almost complete suppression of virus in tail tissues up to 34 days of age was not unexpected since we had observed this in earlier studies using the same or similar IgG preparations made in goats (6) .
The protection against leukemia shown in Table 3 was also impressive. Only six of 30 or 20% of the immunized mice developed fatal leukemia, while 20 of 24 or 83.3% of the nonimmunized controls also died of leukemia.
In the second experiment terminated at 300 days, one of 24 (4.2%) of the test group and 30 of 50 (60%) untreated controls died of leukemia. The degree of protection, which was highly significant in both experiments (P << 0.001), suggested that the serotype-specific immunizations which demonstrably suppressed the normal expression of both the Akv-1 and V-2 virogenes (7), affected some crucial step in the establishment of leukemia. This could result from reduction of the number of virogene copies available for subsequent replication and potential reintegration (8) . Alternatively, the IgG may have an early effect in partially eliminating the hematopoietic cell clones most likely to be at risk for leukemia as indicated by early (9, 10) , (ii) foster nursing of normally high leukemia F1 mice on milk of a low leukemia strain (11), (iii) infections with specified protozoa (12) and (Wv) treatment with interferon (13) . Treatments of AKR mice with a nionsp~e-cific adjuvant such as Bacillus Calmette-Guerin resulted in delay in leukemia incidence and variable reduced amounts of leukemia by 365 days of age (14, 15) . Except for the interferon reports by Gresser (16) (17) (18) . In studies of combined immunological and genetic influences on leukemia, Aoki et al. (19) found that genetic segregation of Gross virus specific antigen provided accurate predictions of leukemia risk in F1 offspring.
It seems clear that AKR antiviral-specific IgG provided the have added protection additional to that furnished by the IgG since the initial IgG suppression of virus at 25 days was poorer than that observed in experiment 1. In any case, these experiments clearly establish that immunoprevention of cancer coded for inherited virogenes (and possible associated oncogenes) is rather readily accomplished with the use of classical antiviral immune mechanisms. These findings, together with our earlier reports of comparable IgG suppression of ecotropic virus in Fj's of several AKR crossbreeding experiments (20) , suggest that it may be possible to suppress known or postulated aberrant gene expression in diseases other than cancer.
Price and his associates (21) recently reported the prevention of carcinogen-induced malignant transformation of rat cells in vitro with the use of specific antiviral IgG prior to treatment with carcinogenic chemicals. This and other successful experiments in which Price and his associates employed both typespecific and heterotypic viral neutralizing antisera for suppression of both virus and transformation provided definitive evidence for the existence of virus specific determinants for transformation, because only type-specific antibodies against virus prevented transformation. These reports provided addi- [4] [5] logarithms of infectious virus units for several weeks after the IgG treatment), unless one presumes that the IgG reacted with critical virogene specified proteins on thymic and bone marrow cell membranes and, in so doing, brought about suppression of normally large amounts of expressed virus. On the other hand, early treatment with IgG antibodies may have eliminated many of the cells which are normally responsible for the critically high levels of virus required to specify high incidences of leukemia by 300-365 days. The level of virus expression, the degree of immunological reactivity towards known viral proteins, and the ultimate cause of death of the surviving 70 treated mice remain to be determined.
The prevention of leukemia in AKR mice suggested additional experiments designed to prevent sarcomas and other cancers which are regularly produced in mice by chemical carcinogens. Thus, we already have evidence that several injections of ecotropic virus-specific IgG antisera given to weanling C3H/f mice before treatment with 200 Ag of 3-methylcholanthrene provided significant protection (P < 0.001) against subcutaneous sarcomas observed at much higher incidences in controls (unpublished observation).
CONCLUSION
In a sense, the IgG protective antibodies might be viewed as probes providing highly specific information concerning the etiology of cancer in mice. It may, therefore, be possible to utilize these or similar antibody "probes" to identify and isolate products involved in experimental animal and human cancer. If it were possible also to produce high-titered IgG antiserum to tumor-specific glycoprotein antigens that would successfully modify or prevent spontaneous leukemias and/or chemically induced tumors in mice, the possibility that similar specific antisera to tumor cell antigens could be produced for use in humans would perhaps appear to be more feasible.
